Ryan Fischesser Biography and Net Worth

Ryan is the Vice President of Finance and Controller for Caribou Biosciences. Ryan began his career in public accounting over a decade ago with a focus on audit and accounting services. In 2012, he co-founded the CPA firm BHLF LLP where he provided audit and outsourced accounting services to clients in the life science, waste management, and airline industries. He received his B.S. degree in Business Administration with an emphasis in financial services from Saint Mary’s College of California and is a licensed Certified Public Accountant in California.

What is Ryan Fischesser's net worth?: The estimated net worth of Ryan Fischesser is at least $431,531.06 as of October 6th, 2022. Mr. Fischesser owns 110,366 shares of Caribou Biosciences stock worth more than $431,531 as of April 18th. This net worth approximation does not reflect any other assets that Mr. Fischesser may own. Learn More about Ryan Fischesser's net worth.
How do I contact Ryan Fischesser?: The corporate mailing address for Mr. Fischesser and other Caribou Biosciences executives is , , . Caribou Biosciences can also be reached via phone at 510-982-6030 and via email at [email protected]. Learn More on Ryan Fischesser's contact information.
Has Ryan Fischesser been buying or selling shares of Caribou Biosciences?: Ryan Fischesser has not been actively trading shares of Caribou Biosciences in the last ninety days. Most recently, Ryan Fischesser sold 10,000 shares of the business's stock in a transaction on Thursday, October 6th. The shares were sold at an average price of $10.80, for a transaction totalling $108,000.00. Following the completion of the sale, the vice president now directly owns 110,366 shares of the company's stock, valued at $1,191,952.80. Learn More on Ryan Fischesser's trading history.
Who are Caribou Biosciences' active insiders?: Caribou Biosciences' insider roster includes Ryan Fischesser (VP), Rachel Haurwitz (Co-Founder), Steven Kanner (Insider), and Barbara McClung (Insider). Learn More on Caribou Biosciences' active insiders.

Ryan Fischesser Insider Trading History at Caribou Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2022	Sell	10,000	$10.80	$108,000.00	110,366
1/11/2022	Buy	7,387	$4.00	$29,548.00
12/20/2021	Buy	1,136	$2.69	$3,055.84
10/11/2021	Buy	1,746	$2.69	$4,696.74

Ryan Fischesser Buying and Selling Activity at Caribou Biosciences

Caribou Biosciences Company Overview

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Today's Range

Now: $3.91

$3.88

$4.02

50 Day Range

MA: $5.88

$3.91

$8.26

2 Week Range

Now: $3.91

$3.44

$8.59

Volume

1,415,632 shs

Average Volume

1,644,391 shs

Market Capitalization

$353.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.47

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story